Columbia Neurosurgery Team Releases Detailed Analysis of Rare Brain Tumor

Researchers from Columbia University’s Department of Neurological Surgery have published a comprehensive systematic review examining supratentorial intraparenchymal schwannomas, a notably uncommon central nervous system tumor. The work, appearing in the October 2026 issue of the Journal of Clinical Neuroscience, combines an illustrative case from their institution with aggregated data from 82 patients across 63 prior publications. Lead author Adrian E. Jimenez, along with co-authors Helen Ellsworth, Gunnar Hargas, Gurcharanjeet Kaur, Peter C. Pan, and senior author Guy M. McKhann, presents quantitative insights into postoperative outcomes, particularly seizure freedom following surgical resection.

The study stands out for its use of individual-patient data meta-analysis and Bayesian statistical modeling to address the challenges of studying such infrequent conditions. Supratentorial intraparenchymal schwannomas originate within the brain parenchyma above the tentorium cerebelli and differ from the more typical vestibular schwannomas that arise along cranial nerves. Schwann cells, which normally myelinate peripheral nerves, are not typically present in this brain region, making the tumor’s pathogenesis an area of ongoing investigation involving theories such as aberrant neural crest cell migration or mesenchymal transformation.

Illustrative Case Highlights Clinical Presentation and Molecular Findings

The authors detail the case of a 23-year-old woman with a history of polycystic ovary syndrome, asthma, and migraines who experienced an incidental discovery of a right frontal enhancing mass measuring approximately 1 by 1.1 by 1.1 centimeters after a concussion in June 2023. Initial imaging suggested a possible meningioma. She later had a likely seizure event in September 2023. Surgical intervention via right frontal craniotomy achieved gross total resection. Pathological examination confirmed a World Health Organization grade I schwannoma. Immunohistochemistry showed positivity for S-100 and SOX-10, negativity for OLIG-2, and positivity for GFAP. Molecular profiling identified a CHD7-VGLL3 fusion, consistent with emerging classifications of vestigial-like family altered peripheral nerve sheath tumors as a distinct category of intraparenchymal central nervous system schwannomas.

This case exemplifies the often incidental or seizure-related presentation of these tumors in younger adults. The patient’s outcome contributes to the broader dataset analyzed in the review, underscoring the value of complete resection when feasible.

Systematic Review Methodology and Scope

The team conducted a PRISMA-compliant systematic review searching PubMed, Cochrane Library, and Scopus through July 2025. Sixty-three articles met inclusion criteria, encompassing publications spanning 69 years and 19 countries. Most reports were single case descriptions or small series, reflecting the extreme rarity of the entity with fewer than 100 documented instances overall. The review focused exclusively on supratentorial locations, distinguishing them from infratentorial counterparts that more commonly present with ataxia or cranial nerve deficits.

Data extraction emphasized patient demographics, tumor characteristics, surgical approaches, and long-term seizure outcomes. The authors applied both nonparametric Kaplan-Meier estimation and a parametric Bayesian Weibull accelerated-failure-time model to derive seizure-free survival estimates under conditions of limited sample size.

Key Findings on Seizure Outcomes and Statistical Insights

Among the 82 patients identified, the meta-analysis yielded a median seizure-free survival time of 133.43 months. Probability estimates indicated 95.28 percent of patients remaining seizure-free at 12 months, 85.00 percent at 36 months, and 74.75 percent at 60 months postoperatively. The observed postoperative seizure-freedom rate of 83.8 percent exceeded the 70 percent benchmark established for low-grade epilepsy-associated neuroepithelial tumors, reaching statistical significance.

These results suggest that surgical resection offers durable seizure control for many individuals with epileptogenic supratentorial intraparenchymal schwannomas. The application of Bayesian methods proved particularly useful for generating credible intervals in a data-sparse environment, providing clinicians with practical probabilistic guidance rather than point estimates alone.

Photo by Tyger Ligon on Unsplash

Pathogenesis, Molecular Advances, and Diagnostic Challenges

Historical literature since the first reported case in 1966 has debated the origin of intraparenchymal schwannomas given the absence of normal Schwann cells in supratentorial parenchyma. Recent molecular work, including identification of VGLL fusions, supports reclassification efforts and improves diagnostic precision beyond traditional histology. The Columbia team’s case adds to this growing body of evidence with the CHD7-VGLL3 fusion detection.

Preoperative differentiation from more common entities such as meningiomas or gliomas remains challenging, often relying on advanced imaging and, increasingly, molecular profiling. The review highlights how these tumors frequently mimic glial neoplasms radiographically, emphasizing the importance of histopathological confirmation.

Implications for Neurosurgical Practice and Research Training

For practicing neurosurgeons and neurologists, the findings reinforce gross total resection as a primary goal when tumors present with seizures or mass effect. The high rates of sustained seizure freedom support early surgical consideration in appropriate candidates. Multidisciplinary collaboration involving neuropathologists and molecular diagnosticians is essential given the evolving classification landscape.

The publication also illustrates opportunities for trainees and early-career researchers. Systematic reviews combined with individual-patient data meta-analyses represent accessible yet impactful projects for residents and fellows seeking to contribute to the literature on rare conditions. Institutions like Columbia University, with strong neuro-oncology and epilepsy surgery programs, provide fertile environments for such work.

Broader Context in Rare Disease Research and Academic Careers

Studies of ultra-rare tumors like supratentorial intraparenchymal schwannomas demonstrate the power of collaborative data synthesis. They also highlight career pathways in academic neurosurgery that blend clinical practice with outcomes research, predictive modeling, and evidence synthesis. PhD-track candidates and postdoctoral researchers in neuroscience or epidemiology may find analogous projects valuable for building expertise in Bayesian statistics or rare-disease registries.

Funding landscapes increasingly support such efforts through targeted grants for orphan diseases and methodological innovation. The absence of dedicated funding for this particular study further illustrates how investigator-initiated work can still yield high-impact results when leveraging existing literature.

Future Directions and Ongoing Questions

Longer-term follow-up across larger cohorts will refine survival estimates. Integration of genomic data into prospective registries could clarify pathogenesis and identify therapeutic targets. Advances in intraoperative imaging and minimally invasive techniques may further improve resection rates while preserving neurological function. Continued molecular characterization promises to refine WHO classification and guide personalized management strategies.

Academic departments worldwide are well positioned to contribute through multi-institutional collaborations that pool scarce cases. Training programs emphasizing research methodology alongside clinical skills prepare the next generation of investigators to tackle similar challenges in neuro-oncology.

Photo by Meadow Marie on Unsplash

Accessing the Full Publication

The complete article, including detailed methods, figures, and the full reference list, is available via ScienceDirect at https://www.sciencedirect.com/science/article/abs/pii/S0967586826003152. A PubMed record provides additional indexing at https://pubmed.ncbi.nlm.nih.gov/42330744. Clinicians and researchers interested in rare central nervous system tumors will find the quantitative seizure-freedom projections particularly actionable for patient counseling.